Cargando…

Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer

Detalles Bibliográficos
Autores principales:	Alsina, Maria, Smyth, Elizabeth C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802958/ https://www.ncbi.nlm.nih.gov/pubmed/31673430 http://dx.doi.org/10.1136/esmoopen-2019-000591

Ejemplares similares

Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer
por: Kang, Connie, et al.
Publicado: (2019)

Biomarkers of Trifluridine-Tipiracil Efficacy
por: Voutsadakis, Ioannis A.
Publicado: (2021)

Correction to: Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer
por: Kang, Connie, et al.
Publicado: (2019)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
por: Chida, Keigo, et al.
Publicado: (2021)

Trifluridine/Tipiracil: Old Drug, New Tricks
por: Jeffers, Kate D.
Publicado: (2016)

Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada
por: Ding, Philip Q., et al.
Publicado: (2022)

Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS
por: Tabernero, Josep, et al.
Publicado: (2020)

Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan
por: Takushima, Yusuke, et al.
Publicado: (2021)

Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil
por: Puthiamadathil, Jeevan M, et al.
Publicado: (2017)

Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication
por: Nakanishi, Ryota, et al.
Publicado: (2017)

Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer
por: Suzuki, Norihiko, et al.
Publicado: (2017)

Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer
por: Suzuki, Norihiko, et al.
Publicado: (2021)

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study
por: Tabernero, J., et al.
Publicado: (2021)

QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer
por: Tabernero, Josep, et al.
Publicado: (2017)

Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
por: Malik, Mateusz, et al.
Publicado: (2021)

Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil
por: Koper, Agnieszka, et al.
Publicado: (2023)

Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
por: Matsumoto, Toshihiko, et al.
Publicado: (2022)

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)
por: Takahashi, Naoki, et al.
Publicado: (2023)

Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
por: García-Alfonso, Pilar, et al.
Publicado: (2021)

Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells
por: Matsuoka, Kazuaki, et al.
Publicado: (2018)

Stratified medicine in practice: review of predictive biomarkers in European Medicines Agency (EMA) indications
por: Malottki, Kinga, et al.
Publicado: (2011)

Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial
por: Ilson, David H., et al.
Publicado: (2019)

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study
por: Mansoor, Wasat, et al.
Publicado: (2021)

The effect of trifluridine/tipiracil for patients with heavily pretreated metastatic gastric cancer: A protocol for systematic review and meta-analysis
por: He, Xiaoyan, et al.
Publicado: (2021)

RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer
por: Koumarianou, Anna, et al.
Publicado: (2023)

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
por: van de Haar, Joris, et al.
Publicado: (2023)

Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)
por: Shitara, Kohei, et al.
Publicado: (2022)

Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression
por: Matsuoka, Kazuaki, et al.
Publicado: (2018)

Clinical Evaluation of the Safety and Efficacy of Trifluridine/Tipiracil in the Treatment of Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Evidence to Date
por: Wheelden, Megan, et al.
Publicado: (2020)

Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
por: Lamarca, A., et al.
Publicado: (2023)

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
por: Kwakman, Johannes J. M., et al.
Publicado: (2017)

Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
por: Sunakawa, Yu, et al.
Publicado: (2017)

Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
por: Patel, Anuj K., et al.
Publicado: (2019)

Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer
por: Nukatsuka, Mamoru, et al.
Publicado: (2023)

Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
por: Tabernero, Josep, et al.
Publicado: (2020)

Dramatic Response in a Patient with Metastatic Gastric Cancer Using Trifluridine/Tipiracil after Rapid Disease Progression while on Nivolumab
por: Nozawa, Kazuki, et al.
Publicado: (2020)

A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone
por: Cleary, James M., et al.
Publicado: (2017)

Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
por: Kamiimabeppu, Daisaku, et al.
Publicado: (2021)

Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis
por: Yoshino, Takayuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tpsdotujv4lt156ornfb76flo9